12 analysts have expressed a variety of opinions on Genmab (NASDAQ:GMAB) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $46.83, along with a high estimate of $50.00 and a low estimate of $31.00. This current average represents a 3.54% decrease from the previous average price target of $48.55…